Mirati Ther

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. Show More...

  • Website https://www.mirati.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 58.70 USD
  • Last Updated 23-01-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -18.0 -1.5 -2.04 -4.78 -3.24 -3.82 -4.2 -2.78 -3.19 -5.69 -6.54
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 6.0 10.0 11.0 13.0 17.0 20.0 25.0 31.0 37.0 39.0
    Book Value Per Share * USD 5.02 4.72 -1.75 2.63 6.94 3.28 2.38 6.92 10.99 15.04
    Free Cash Flow Per Share * USD -19.45 -2.87 -2.77 -2.35 -2.82 -3.47 -2.86 -2.14 -3.55
    Return on Assets % -92.03 -45.51 -57.54 -101.34 -89.14 -79.89 -86.85 -63.88 -51.03 -64.43 -50.63
    Financial Leverage (Average) 2.69 1.14 1.16 2.49 1.19 1.08 1.31 1.1 1.13 1.13 1.09
    Return on Equity % -183.63 -60.96 -66.08 -175.35 -161.95 -88.22 -99.88 -73.58 -57.08 -72.91 -55.1
    Return on Invested Capital % -173.6 -62.03 -66.57 -176.02 -161.95 -88.22 -99.88 -73.58 -57.08 -72.91 -55.1
    Interest Coverage -472.77 -356.75 -651.1
    Current Ratio 1.91 8.13 7.36 12.24 6.05 12.8 3.97 11.42 8.67 8.68 12.58
    Quick Ratio 1.74 7.63 7.16 12.1 5.6 12.51 3.79 11.07 8.55 8.52 12.44
    Debt/Equity